abiraterone-acetate and Hemolysis

Abiraterone acetate (ABRTA) is clinically beneficial in management of metastatic castration-resistant prostate cancer (PC-3). With highlighted low solubility and permeability, orally hampered treatment of ABRTA necessitate high dose to achieve therapeutic efficacy. To triumph these challenges, we aimed to develop intestinal lymphatic transport facilitating lipid-based delivery to enhance bioavailability. ABRTA-containing self-nano emulsified drug delivery (ABRTA-SNEDDS) was statistically optimized by D-optimal design using design expert. Optimized formulation was characterized for particle size, thermodynamic stability,

Topics: Abiraterone Acetate; Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Drug Delivery Systems; Hemolysis; Liposomes; Lymph; Male; Nanoparticles; Rats; Rats, Sprague-Dawley